Compass Pathways collaborates with Mindful Health Solutions on scalable COMP360 psilocybin treatment model

LONDON, May 2, 2024 – Compass Pathways plc, a biotechnology firm listed on Nasdaq (CMPS), has partnered with Mindful Health Solutions (MHS), a key provider of innovative behavioral health care in the U.S., to develop a scalable and cost-effective delivery model for COMP360 psilocybin treatment for treatment-resistant depression (TRD). This partnership aims to enhance the understanding of different approaches to deliver COMP360 to patients in various care settings.

MHS is known for its comprehensive mental health services, particularly for individuals with TRD and other mental health conditions. Their holistic care model integrates advanced interventional treatments, medication management, and psychotherapy. With over 20 outpatient clinics in California, Washington, Texas, and Georgia, MHS is ideally positioned to provide insights on delivering COMP360 psilocybin treatment.

Kabir Nath, CEO of Compass Pathways, emphasized the importance of understanding how different mental health service providers can deliver COMP360 psilocybin treatment if it receives FDA approval. By collaborating with MHS, Compass aims to gain valuable insights from a leading provider of innovative behavioral health care for those with treatment-resistant depression and other challenging mental health conditions.

The partnership will involve a thorough exchange of information on Compass's delivery model for COMP360 psilocybin treatment and its integration into a healthcare system like MHS. The collaboration will map the patient pathway for those with depression and TRD, exploring challenges in the current care experience and addressing them. MHS will engage in training sessions on Compass’s psychological support model and therapist training program, conducting research to understand therapist training needs better. Additionally, the exchange will cover model treatment rooms, site activation services, and considerations for coding and reimbursement related to psychedelic treatments.

John Minahan, CEO of Mindful Health Solutions, highlighted the collaboration's significance, noting the millions of individuals in the U.S. whose depression is unresponsive to existing treatments. MHS’s mission is to make innovative treatments accessible to those who can benefit from them. By partnering with Compass Pathways, MHS aims to contribute to understanding the most effective delivery methods for COMP360 psilocybin treatment for TRD, pending approval.

Compass has entered into similar research collaboration agreements with other organizations, including Greenbrook TMS, Hackensack Meridian Health, and Journey Clinical. These partnerships aim to explore the delivery of innovative psychiatric treatments, such as transcranial magnetic stimulation and psychedelic-assisted psychotherapy, to individuals with TRD.

Compass Pathways is focused on accelerating patient access to evidence-based innovations in mental health. The company's proprietary synthetic psilocybin formulation, COMP360, is administered with psychological support and has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for TRD. Currently, Compass is conducting a phase 3 clinical program for COMP360, the largest randomized, controlled, double-blind psilocybin treatment trial ever conducted. Previous phase 2b studies showed significant improvements in depressive symptoms after three weeks for patients who received a single 25mg dose of COMP360 with psychological support. Compass is also investigating COMP360 for post-traumatic stress disorder (PTSD) and anorexia nervosa.

Mindful Health Solutions is a prominent behavioral health care provider in the U.S., specializing in emerging psychedelic research, precision medicine, and advanced treatment protocols such as transcranial magnetic stimulation, esketamine, and IV Ketamine for individuals with TRD and other serious mental illnesses. With over 20 outpatient clinics, MHS is committed to improving the lives of patients, particularly those suffering from depression.

Through this collaboration, Compass Pathways and Mindful Health Solutions aim to advance the delivery of innovative treatments for mental health conditions, potentially transforming care for individuals with TRD.